Department of Biological Sciences, College of Arts and Sciences, University of Alaska Anchorage, Anchorage, Alaska, United States.
Department of Biology, University of Wisconsin Oshkosh, Oshkosh, Wisconsin, United States.
Physiol Genomics. 2024 Nov 1;56(11):711-720. doi: 10.1152/physiolgenomics.00034.2024. Epub 2024 Sep 9.
The gut microbiome is essential for maintaining organismal health. Gut microbiota may be disrupted through external factors like dietary change, which can lead to gut inflammation, resulting in obesity. Hibernating mammals develop low-grade gut inflammation when they accumulate fat deposits in preparation for hibernation, making them useful models for studying the relationship between the microbiome, inflammation, and weight gain. Nonsteroidal anti-inflammatory drugs and steroids are commonly used in humans to target gut inflammation, but how these drugs affect the gut microbiome and its stability is unclear. We investigated the effect of the glucocorticoid drug budesonide on the gut microbiome and cytokine levels of an obligate hibernator, the 13-lined ground squirrel, during the fattening season. We used 16S rRNA gene sequencing to characterize bacterial communities in the lumen and mucosa of the cecum and colon and measured proinflammatory [tumor necrosis factor-α (TNF-α)/interleukin 6 (IL-6)] and anti-inflammatory (IL-10) cytokine levels. Budesonide affected the microbiome only in the cecum lumen, where bacterial diversity was higher in the control group, and communities significantly differed between treatments. Across gut sections, and were significantly higher in the budesonide group, whereas was higher in the control group. TNF-α and IL-6 levels were higher in control squirrels compared with the budesonide group, but there was no difference in IL-10 levels. Overall, budesonide treatment affected the microbial community and diversity of 13-lined ground squirrels in the cecum lumen. Our study presents another step toward developing ground squirrels as a model for studying the interaction between the microbiota and host inflammation. Disruptions of gut microbiota can lead to inflammation, resulting in weight gain. Inflammation can be treated with budesonide, but how budesonide affects gut microbiota is unclear. Thirteen-lined ground squirrels experience low-grade gut inflammation during prehibernation fattening, which compares with human inflammation-weight gain mechanisms. We showed that budesonide treatment decreased microbiome diversity and lead to a shift in community in the cecum lumen. Our study supports developing ground squirrels as a model for studying microbiome-inflammation interactions.
肠道微生物组对于维持机体健康至关重要。肠道微生物可能会受到饮食变化等外部因素的干扰,从而导致肠道炎症,进而导致肥胖。在为冬眠做准备而积累脂肪储备时,冬眠哺乳动物会出现低水平的肠道炎症,这使它们成为研究微生物组、炎症和体重增加之间关系的有用模型。非甾体抗炎药和类固醇在人类中常用于靶向肠道炎症,但这些药物如何影响肠道微生物组及其稳定性尚不清楚。我们研究了糖皮质激素药物布地奈德对在增肥季节的一种必需冬眠动物——13 条纹地松鼠的肠道微生物组和细胞因子水平的影响。我们使用 16S rRNA 基因测序来描述盲肠和结肠腔和黏膜中的细菌群落,并测量促炎(肿瘤坏死因子-α(TNF-α)/白细胞介素 6(IL-6))和抗炎(IL-10)细胞因子水平。布地奈德仅影响盲肠腔中的微生物组,其中对照组的细菌多样性更高,且处理之间的群落差异显著。在整个肠道部分,布地奈德组的 和 显著升高,而对照组的 升高。与布地奈德组相比,对照组的 TNF-α和 IL-6 水平更高,但 IL-10 水平没有差异。总体而言,布地奈德处理影响了 13 条纹地松鼠盲肠腔中的微生物群落和多样性。我们的研究为将地松鼠发展成为研究微生物组和宿主炎症相互作用的模型又迈进了一步。肠道微生物组的破坏可导致炎症,从而导致体重增加。炎症可以用布地奈德治疗,但布地奈德如何影响肠道微生物组尚不清楚。在冬眠前增肥期间,13 条纹地松鼠经历低水平的肠道炎症,这与人类炎症-体重增加机制相似。我们发现布地奈德处理降低了微生物组的多样性,并导致盲肠腔中的群落发生转移。我们的研究支持将地松鼠发展成为研究微生物组-炎症相互作用的模型。